Betts and Davila eradicated human CD83+ pathogenic CD4+ T cells, proinflammatory DCs, and AML cells by redirecting donor T cells to express an anti-CD83–expressing chimeric antigen receptor (29), adding another dual-purpose immune-based GVHD and GVL strategy. Here, CD83 is linked to graft versus host disease.